Literature DB >> 2128095

Three cases of acquired factor VIII: C inhibitors in non-hemophilic patients.

D Söhngen1, W Köster, B M Kuntz, S Glück, W Schneider.   

Abstract

During the last ten years we observed three non-hemophilic patients with factor(F) VIII: C inhibitors (2 women aged 68 and 80 and a man aged 51). In all three cases, a sudden bleeding tendency was observed shortly after an injury or surgery. Coagulation tests showed a prolonged aPTT and a decreased F VIII: C level. Other deficiencies of blood-clotting factors and acquired or hereditary von Willebrand's disease could be excluded. Therapy with F VIII: C concentrate, cryoprecipitate, or fresh-frozen plasma did not produce the expected increase in F VIII: C. Measurement of F VIII: C inhibitor levels (Bethesda Units, BU) revealed values in the range between 9 and 64 BU. The two patients subjected to long-term therapy with a combination of prednisone (initially 2-3 mg/kg BW) and azathioprine (2-3 mg/kg BW) responded positively; the F VIII: C concentration increased. The third patient, treated only with a low dose of prednisone (30 mg/day), did not show any reaction at all. Since hereditary hemophilia A could be excluded, the inhibitors apparently were acquired. Malignant tumors did not appear. In conclusion, long-term therapy of an acquired F VIII: C inhibitor with a combination of prednisone and azathioprine may lead to complete disappearance of the inhibitor, normalization of the coagulation tests, and complete remission of the bleeding tendency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2128095     DOI: 10.1007/bf01649308

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  14 in total

1.  Letter: A more uniform measurement of factor VIII inhibitors.

Authors: 
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

2.  MEASUREMENT OF PLATELET ADHESIVENESS. A SIMPLE IN VITRO TECHNIQUE DEMONSTRATING AN ABNORMALITY IN VON WILLEBRAND'S DISEASE.

Authors:  E W SALZMAN
Journal:  J Lab Clin Med       Date:  1963-11

3.  [Need for the determination of the plasma kallikrein-kinin system in blood preparations].

Authors:  H T Brüster; J W Scheja
Journal:  Beitr Infusionther Klin Ernahr       Date:  1987

Review 4.  [Thrombophilic and hemorrhagic diatheses in cancer].

Authors:  R Marx
Journal:  Thromb Diath Haemorrh Suppl       Date:  1968

5.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

6.  Thawing of fresh-frozen plasma with a new microwave oven.

Authors:  D Söhngen; V Kretschmer; K Franke; H Pelzer; W H Walker
Journal:  Transfusion       Date:  1988 Nov-Dec       Impact factor: 3.157

7.  The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors.

Authors:  M W Hilgartner; G L Knatterud
Journal:  Blood       Date:  1983-01       Impact factor: 22.113

8.  Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII.

Authors:  P B Kernoff; N D Thomas; P A Lilley; K B Matthews; E Goldman; E G Tuddenham
Journal:  Blood       Date:  1984-01       Impact factor: 22.113

9.  A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.

Authors:  D Green; K Lechner
Journal:  Thromb Haemost       Date:  1981-06-30       Impact factor: 5.249

10.  Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.

Authors:  J M Lusher; S S Shapiro; J E Palascak; A V Rao; P H Levine; P M Blatt
Journal:  N Engl J Med       Date:  1980-08-21       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.